Molecular Tumor Board: 68 year-old female with Stage IV lung adenocarcinoma and EGFR and KRAS mutations on liquid biopsy

This latest molecular tumor board reviews a case of a 68 year-old female with metastatic lung adenocarcinoma with an EGFR L848R mutation. Frontline biomarker testing provided initial options for therapy, but at progression liquid biopsy testing was confounded by clonal hematopoiesis.